Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hepatocellular carcinoma in 2017

Two large steps forward, one small step back

In 2017, the FDA approved regorafenib and nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib treatment, opening the door for an effective systemic second-line therapy in advanced disease. By contrast, the addition of sorafenib to transarterial chemoembolization with drug-eluting beads did not improve progression-free survival in the intermediate disease stage.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Sequential treatment requires a timely switch from transarterial approaches to systemic treatment in patients with well-preserved liver function.


  1. Bruix, J., Reig, M. & Sherman, M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150, 835–853 (2016).

    Article  Google Scholar 

  2. Galle, P. R. et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J. Hepatol. 67, 173–183 (2017).

    Article  Google Scholar 

  3. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  Google Scholar 

  4. Worns, M. A. & Galle, P. R. HCC therapies — lessons learned. Nat. Rev. Gastroenterol. Hepatol. 11, 447–452 (2014).

    Article  Google Scholar 

  5. Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).

    Article  CAS  Google Scholar 

  6. El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).

    Article  CAS  Google Scholar 

  7. Crocenzi, T. S. et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma: CheckMate 040 study [abstract]. J. Clin. Oncol. 35, 4013 (2017).

    Article  Google Scholar 

  8. Lencioni, R. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J. Hepatol. 64, 1090–1098 (2016).

    Article  CAS  Google Scholar 

  9. Meyer, T. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol. Hepatol. 2, 565–575 (2017).

    Article  Google Scholar 

  10. Finn, R. et al. Outcomes with sorafenib followed by regorafenib or placebo for hepatocellular carcinoma (HCC): results of the international, randomized phase 3 RESORCE trial (abstract). J. Clin. Oncol. 35, 344 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Peter R. Galle.

Ethics declarations

Competing interests

M.-A.W. has received consulting and lecture fees from Bayer and Bristol-Myers Squibb. P.R.G. has received consulting and lecture fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, MSD/Merck, Roche, Sillajen, and Sirtex.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wörns, MA., Galle, P. Two large steps forward, one small step back. Nat Rev Gastroenterol Hepatol 15, 74–76 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer